Ozone Pharmaceuticals has started clinical trials of a biotech drug

Ozon Pharmaceuticals has received approval from the Ministry of Health to conduct a comparative randomized clinical trial on the pharmacokinetics and safety of the seventh biotech drug. It is intended for the treatment of juvenile arthritis, rheumatoid arthritis, psoriatic arthritis. A total of 28 biosimilars are at different stages of development and registration in the company.